Loading…
for educational and safety purposes
sci-wiki~$open stack topical-hair-loss
stopping the loss, at the follicle, with the androgen pressure removed
3 items; 3 structures drawn from pubchem.
⚠️ IT IS AN EITHER/OR AT THE TOP: pyrilutamide, also called KX-826, OR RU-58841, not both. They are both topical non-steroidal androgen receptor antagonists and stacking two of them is not what this is.
The difference between the two arms is entirely a difference in evidence, and that is the whole basis for choosing. RU-58841 has no completed human development programme; it was abandoned decades ago and is sold as a research chemical, which means no efficacy data, no safety data and no manufacturing standard. Pyrilutamide has been through company-run trials, and ⚠️ those results should be read as they actually are: mixed, with some endpoints missed and results that have not established it as a clear success.
GHK-Cu is a copper-binding tripeptide with a real wound-healing literature and a follicle literature that is thinner but present.
AHK-Cu is a related copper tripeptide with a considerably thinner evidence base, and marked optional for that reason.
⚠️ COMPANION TO THE HAIR REGROWTH STACK, and the difference matters for choosing between them: this one is about stopping loss through androgen receptor antagonism, that one is about regrowth through minoxidil and Wnt signalling. Two of the items overlap, which is honest since the two goals genuinely share tools, but a reader who is still losing hair wants this one first.
This stack is about removing a pressure rather than adding a stimulus, and that distinction separates it from the regrowth stack.
Androgenetic alopecia is driven by dihydrotestosterone acting at androgen receptors in genetically susceptible follicles, progressively miniaturising them. A topical androgen receptor antagonist blocks that signal at the follicle itself, which is the whole design intent: local antagonism without the systemic antiandrogen load that finasteride or oral antiandrogens produce.
The copper peptides work on the surrounding matrix rather than on the androgen axis. GHK-Cu has a genuine wound-healing literature and is proposed to affect the follicle environment through remodelling and angiogenic signalling; AHK-Cu is related and thinner-evidenced, which is why it is marked optional rather than treated as an equal.
The honest structure is one item doing the mechanistic work and two supporting the tissue it works in.
Nothing acute, and hair timescales are the slowest on this page. The follicle cycle means no intervention shows a visible result in under three to four months, and six to twelve is the honest window for judging one.
The practical consequence is that photographs at fixed lighting and fixed intervals are worth far more than impressions, because gradual change is exactly what human perception is worst at.
Anyone who concludes at week six that it is not working has not yet given the follicle time to complete a cycle.
⚠️ TOPICAL DOES NOT MEAN SYSTEMIC ABSORPTION IS ZERO, and the named mechanism is systemic antiandrogen exposure: reduced libido, mood effects and, in men, gynaecomastia are all documented consequences of androgen receptor antagonism wherever it happens. The local-only premise is the design goal rather than a measured guarantee. ⚠️ ANDROGEN ANTAGONISTS ARE UNSAFE IN PREGNANCY because of the risk to a male foetus, and handling matters as well as use. RU-58841 has no human safety data at all.
nothing flaggedcurated roster
every pair here reads as compatible on the mechanisms the site holds. that is the absence of a known conflict, not a clearance.
all in one basketRUO; Code Sean
3 of 3 priced
1 overlapsame lever, twice
interested in protocols? join the discord; that is where dosing, timing and the practical side get discussed.
the sci-wiki publishes this as a description of what these compounds do together, not as a recommendation to take them. Nothing here is medical advice.